Press Releases

July 12, 2017

Neuraltus Announces Completion of Enrollment in Confirmatory Phase 2 Study of NP001 in ALS Patients with Systemic Inflammation

April 3, 2017

Retrospective Analysis Finds Amyotrophic Lateral Sclerosis Patients with High Serum C-Reactive Protein (CRP) Levels May Respond to Immune Regulators Like NP001

February 8, 2017

Neuraltus Pharmaceuticals Provides Enrollment Update on Confirmatory Phase 2 Study of NP001 in ALS

September 22, 2016
Neuraltus Pharmaceuticals Initiates Confirmatory Phase 2 Study of NP001 in Patients with Amyotrophic Lateral Sclerosis

April 4, 2016
Neuraltus Pharmaceuticals Announces Plans for Second Phase 2 Study of NP001 in ALS Using Biomarker for Enriched Patient Selection

Biomarker Analyses of Neuraltus Pharmaceuticals’ NP001 Phase 2 Data Demonstrate Potential for Treating ALS Patients with Systemic Inflammation

September 21, 2015
Neuraltus Pharmaceuticals and Clinigen Group Announce Partnership to Initiate a Managed Access Program for Investigational ALS Therapy in Europe

July 1, 2015
Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001

April 20, 2015
Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals’ NP001 Potential Efficacy and Safety in ALS

December 9, 2013
Neuraltus Pharmaceuticals' NP001 Phase 2 Results Highlighted at the 24th International Symposium on ALS/MND

October 8, 2013
Neuraltus Pharmaceuticals Names Richard L. Casey as President and Chief Executive Officer

October 29, 2012
Neuraltus Pharmaceuticals Announces Phase 2 Clinical Results for NP001 in Patients with Amyotrophic Lateral Sclerosis (ALS)